key: cord-0766875-inqggk2h
authors: George, Michael; Danila, Maria I.; Watrous, Daniel; Reddy, Shanmugapriya; Alper, Jeffrey; Xie, Fenglong; Nowell, W. Benjamin; Kallich, Joel; Clinton, Cassie; Saag, Kenneth G.; Curtis, Jeffrey R.
title: Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID19 Pandemic in a Community Practice‐Based Network
date: 2021-05-10
journal: Arthritis Care Res (Hoboken)
DOI: 10.1002/acr.24626
sha: d7aa94ed27ddfd59352e19d9028b34875c7218e4
doc_id: 766875
cord_uid: inqggk2h

BACKGROUND: The effect of the COVID19 pandemic on community‐based rheumatology care and use of telehealth is unclear. METHODS: Using a community practice‐based rheumatologist network, we examined trends in in‐person vs. telehealth visits vs. canceled visits in three time periods: pre‐COVID19, COVID19‐Transition (6‐weeks beginning 3/23/20), and post‐COVID19‐Transition (May‐August). In the Transition period, we compared patients who received in‐person care vs. telehealth visits vs. cancelled all visits. We used multivariable logistic regression to identify factors associated with canceled or telehealth visits. RESULTS: Pre‐COVID19, there were 7,075 visits/week among 60,002 unique rheumatology patients cared for by approximately 300 providers practicing in 92 offices. This decreased substantially (24.6% reduction) during COVID19‐Transition period for in‐person but rebounded to pre‐COVID19 levels during post‐COVID19 transition. There were almost no telehealth visits pre‐COVID19, but telehealth increased substantially during the COVID19‐Transition (41.4% of all follow‐up visits) and slightly decreased during post‐COVID19‐Transition (27.7% of visits). Older age, female sex, Black or Hispanic race/ethnicity, lower socioeconomic status, and rural residence were associated with greater likelihood of cancelling visits. Most factors were also associated with a lower likelihood of having telehealth vs. in‐office visits. Patients living further from the rheumatologists’ office were more likely to use telehealth. CONCLUSION: COVID19 led to large disruptions in rheumatology care; these disruptions were only partially offset by increases in telehealth use and disproportionately affected racial/ethnic minorities and patients with lower socioeconomic status. During the COVID‐19 era, telehealth continues to be an important part of rheumatology practice, but disparities in access to care exist for some vulnerable groups.

Telehealth use in rheumatology prior to the COVID-19 pandemic was primarily limited to treating patients in rural areas that were medically under-served [1] [2] . The COVID-19 pandemic, however, has led to substantial healthcare disruptions and a rapid rise in telehealth use among patients with rheumatic and musculoskeletal diseases (RMDs) [3] [4] [5] [6] . Many of these patients are at increased risk of infection and may be at increased risk of severe COVID-19 due to immune dysregulation from their rheumatic condition, immunosuppressive medications, or multiple comorbid health conditions (i.e. multimorbidity) [7] [8] [9] . Concerns about COVID-19 may further exacerbate healthcare disruptions in this population, yet these patients also require frequent healthcare visits for the evaluation and management of their conditions. Telehealth, defined as the use of electronic information and telecommunications technologies to support long-distance clinical health care, [10] offers an attractive alternative to face-to-face visits for at least a subset of patients, especially for those with an already-established diagnoses from their rheumatology provider.

Little is known, however, about the patterns of healthcare disruptions and telehealth use in rheumatology practices during the pandemic, or the degree to which vulnerable patient populations have been disproportionately affected. We sought to understand the impact of the pandemic on rheumatology care in the setting of a large rheumatology community practice-based network. We described use of telehealth services within this provider network and tested the hypothesis that social determinants of health, including age, sex, race/ethnicity, socioeconomic status, and geographic location would influence missed rheumatology visits or infusion therapies given at rheumatology offices. We also evaluated whether these same social determinants of health [11] [12] [13] [14] were associated with use of telehealth services.

We extracted the analytic cohort from the Columbus electronic health record (EHR) data warehouse of the American Arthritis and Rheumatology Associates (AARA) network, which represents approximately 300 full time practicing rheumatology clinicians across 27 states. AARA and its business affiliate Bendcare is the largest U.S. super group of rheumatology specialist providers in the U.S. and was founded to promote high-quality, value-based rheumatology care within the context of a community practice-based network. Its providers use a common EHR system with an embedded video-based telehealth platform. Structured and selected unstructured data elements are normalized to a common data model, and the EHR data is augmented by a variety of internal and external data feeds including patient reported outcome (PRO) data from the NIH PROMIS system [15] and linked lab, pharmacy, and health plan claims data from several sources. This infrastructure supports both prospective and retrospective clinical projects, quality improvement initiatives, and research studies.

This article is protected by copyright. All rights reserved Telehealth services were defined based on billed visits from the Evaluation and Management (E&M) Current Procedure Terminology (CPT®) Code Set (e.g. 99214) that included the modifiers '-95', '-GT', and '-GQ', reflecting use of synchronous or asynchronous telecommunication services. The CPT codes for phone visits (i.e. 99441-3), and digital evaluation and management services (99421-3), and virtual visits (G2010, G2012) were also included. In person visits were also identified using similar CPT codes without the telehealth modifiers, and visits were stratified as to whether they were for consultations/new patient encounters vs. return patient visits for established patients.

We examined calendar trends in the frequency of in-person vs. telehealth (video and/or phone) visits in 2020 over all AARA practices. The key intervals of time were subdivided a priori into the pre-COVID19 time interval (i.e. first full 10 weeks of 2020), the COVID19-Transition period (i.e. week 12 of 2020, beginning the week of March 23 th , and the ensuing 6 weeks), and the post-COVID19-Transition interval (i.e. beginning the week of May 4 th ). The Transition interval was anchored at Week 12 given multiple news and public health authority announcements that recommended social distancing and encouraged restriction of discretionary travel [16] . The data were censored at September 1 st to allow for complete adjudication of billed visits and healthcare services. Scheduling data from the EHR was used to examine whether visits were cancelled or missed (i.e. 'no show'), or kept, stratified by visit type. Cancelled/missed visits that were rescheduled within the same time period (i.e. COVID19-Transition period) were considered kept. We included in this evaluation administration for intravenous (IV) rheumatology therapies typically given in a provider's office, focusing on treatments for rheumatoid arthritis (RA) that included IV abatacept, IV tocilizumab, IV golimumab, and infliximab.

In addition to age, sex, and race/ethnicity, we evaluated a number of additional social determinants of health. Factors of interest included the national percentile ranking of the Area Deprivation Index (ADI) [17] . The ADI is based on the American Community Survey [18] and ranks neighborhoods by socioeconomic status disadvantage within either the entire U.S. (used for this analysis), or at a state level. It encompasses domains of income, education, employment, and housing quality and is based on census block group, obtained by use of patients' individual 9-digit zip code. We also evaluated the door-to-door driving distance between each patients' residence and their rheumatologists' office address, 

This article is protected by copyright. All rights reserved

Among the subset of patients with RA who had disease activity measured using the Clinical Disease Activity Index (CDAI) available both in the pre-COVID19 period and in the post-COVID19-Transition period at in-person visits, we examined the within-person change in CDAI to assess whether patients experienced disease activity worsening in the COVID19-Transition period. While some practices did collect CDAIs during telehealth visits, the methods by which this data were collected were highly variable across practices, and these CDAI observations were therefore excluded.

Additionally, to evaluate the hypothesis that COVID19 reduced clinician and patients' willingness to start a new targeted RA therapy, we examined the likelihood that patients would start a new biologic or Janus kinase inhibitor (JAKi) treatment in the COVID19-Transition period. The analysis was restricted to rheumatology practices that contributed data both in 2019 and 2020, and we compared the likelihood of treatment initiation during that 6-week interval to the corresponding 6-week interval in spring 2019.

Given the expectation that the COVID19-Transition period would create the greatest disruption in rheumatology care, we focused on that 6-week interval. As we observed that telehealth services were minimally deployed for new patients, we compared the characteristics of established rheumatology patients who received in-person care, telehealth care, or who cancelled any/all scheduled rheumatology visits with their clinician. Categories were mutually exclusive and applied in a hierarchical fashion such that someone who (for example) had a visit cancelled but rescheduled it and received both in-person and telehealth care during the 6 weeks period would be counted only in the in-person care category. We compared demographics, main rheumatology diagnosis, and measures of social determinants of health as described above. Standardized mean differences (SMD) were used to compare these three groups, with values >0.10 indicative of potentially important differences [21] .

We used multivariable logistic regression models were used to identify factors associated with canceled vs. any completed visits (i.e. telehealth or in-person visits). In separate models we compared those who underwent a telehealth vs. an in-person visit during the COVID19-Transition period. The main independent variables of interest were the social determinants of health described above. Because some factors related to geography were modestly correlated with one another, not all could be examined in multivariable models; factors of highest interest were retained. Given the clustered nature of the data (patients nested within physician practices), alternating logistic regression was used to adjust for and estimate the effects of practice-level effects. The proportion of all visits conducted as a telehealth visit, rather than an in-person visit, was quantified for each physician practice. In order to evaluate the hypothesis that greater telehealth volume might somewhat offset reduced total visit volume during the COVID19-Transition period, we plotted Accepted Article the proportion of visits conducted as telehealth, ranging from 0%, reflecting no use of telehealth, to 100%, indicating that all visits during this interval were conducted using as telehealth. This proportion was plotted as a function of the mean weekly visit volume during the COVID-Transition period compared to the pre-COVID period, and plotted as a ratio.

A ratio close to 1 would indicate that for any given office, visit volume during the COVID19-Transition period was the same as during the pre-COVID interval.

The within-person changes in CDAI in the Pre-COVID19 and Post-COVID19-Transition Period were evaluated with paired t-tests. Logistic regression was used to model the likelihood of treatment initiation in the COVID19-Transition Period vs. the corresponding interval in 2019, controlling for practice-level clustering as described above. The study received institutional review board (IRB) approval and patient consent was waived. All data analyses were conducted in SAS 9.4 and R 4.0.3.

A total of 126,550 patients contributed 303,037 unique visit days in which one or more encounters occurred in 2020. In the first 10 full weeks of 2020 (pre-COVID), the mean (standard deviation) number of weekly visits across all visit types Table 1 shows characteristics of the 50,988 established rheumatology patients who cancelled, had in-person visits, or who had telehealth visits during the COVID19-Transition interval. Older patients were more likely to cancel visits and less likely to have telehealth-only care. Non-White race, lower socioeconomic status proxied by the Area Deprivation Index, U.S. region, and greater COVID-19 activity in the patient's county of residence were associated with cancelling and having in person visits rather than telehealth care alone.

After multivariable adjustment, the factors independently associated with cancelling all return visits in the COVID19-Transition period ( Table 2 , left column) included older age, female sex, Black race, Hispanic ethnicity, lower socioeconomic status, and rural residence. Compared to patients with RA, patients with gout, osteoarthritis and osteoporosis were more likely to cancel all visits and not reschedule them. Most but not all these same factors were associated with lesser use of telehealth compared to having an in-person visit ( Table 2 , right column, Figure 3 ). Factors associated with a lower likelihood to have a telehealth visit included older age, male sex, lower socioeconomic status, and rural residence. Greater driving distance from the rheumatologists' office was associated with a greater likelihood to have a telehealth visit.

The proportion of all visits delivered via telehealth was highly variable across different rheumatology practices (Figure 4 ).

In some offices, telehealth comprised almost 100% of visits during the COVID19-Transition period (i.e. the highest points on the y axis), whereas at other offices, there was no telehealth use. There was no association between use of telehealth and the reduction in visit volume in the COVID19-Transition period compared to pre-COVID19 levels ( Figure 4 , x axis).

Likewise, there was no association between use of telehealth and practice size (not shown). After multivariable adjustment for demographics, social determinants of health, and primary rheumatologic diagnosis, patients receiving care at offices with greater telehealth use were 4.32-fold more likely to receive telehealth than at offices with lesser use of telehealth services (Supplemental Table) . This practice-level effect was larger in magnitude than all other demographic and social determinant of health-related factors that we studied, although most of these remained significant. Practice site likewise was associated with a greater likelihood that patients cancelled visits (adjusted OR=1.54, 95% CI 1.18, 2.02).

Among people who had both a CDAI in the pre-COVID19 and post-COVID19-Transition period (n=2,741, baseline mean CDAI=13.8), the mean within-person change in the CDAI was less than 1 unit, reflecting no meaningful change. Related to medication initiation in the COVID19-Transition Period, and after controlling for practice-level clustering, the odds of starting a new biologic or JAKi therapy for an RA patient was substantially lower (adjusted odds ratio=0.55, 95%CI 0.50-0.61) compared to the corresponding 6-week period of time in 2019.

In this analysis of telehealth use in a large, multi-state, U.S. community practice-based rheumatology network , we found that telehealth care was essentially non-existent in the pre-COVID era, grew rapidly to comprise almost half of all followup clinic visits as the COVID-19 pandemic evolved, and later stabilized to comprise approximately one-fourth of all follow-up visits. Telehealth appeared to be a substitute for in-person visits, and one of the drivers of more visit Accepted Article cancellations was lower use of telehealth. Of major concern, several important social determinants of health -older age, lower socioeconomic status, and rural residence -were associated with a lower likelihood of having telehealth visits and a greater likelihood of cancelling all visits. Further driving distance from the rheumatology office was associated with greater telehealth use, presumably related to the convenience of telehealth for patients with longer driving distances. In this context, the reduced use of telehealth among patients from rural areas is particularly striking and highlights the complex social and socioeconomic factors contributing to inequities among patients in rural areas.

We also identified other factors associated with telehealth use. Patients with certain autoimmune rheumatic diseases (e.g. rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus) were less likely to cancel visits during the COVID-19 transition period compared to patients with gout, osteoarthritis, and osteoporosis, perhaps reflecting the need for close follow-up or medication monitoring among patients with autoimmune conditions. Individual office practice in delivering telehealth also had a large effect on whether patients received these services, suggesting that some rheumatology practices were able to convert and adapt their practices to deliver care via telehealth, while others made minimal use of it. While reasons for this high practice-level variability are unclear, the ratio of office staff to patients, access to telehealth technology within each provider's office and comfort with its use, and the case mix of individual physician practices may all be influential.

Prior to COVID-19, the use of telehealth in rheumatology received limited attention and use was largely confined to highly selected settings such as the Alaska Tribal Health system [1] . Since the pandemic began, however, the use of telehealth has emerged as a tool to help mitigate disruptions in healthcare, with a variety of applications across healthcare [22] [23] [24] . Several reports have described the impact of the COVID19 pandemic on patient behaviors and healthcare delivery. For example, surveys of patients with autoimmune RMDs have shown that approximately 10-15% stopped their rheumatology treatments during the pandemic, usually without the recommendation or knowledge of their rheumatology provider [4, 25] . At the height of the COVID19-Transition period, the proportion of patients skipping office visits and/or required laboratory monitoring tests was as high as 50% [25] . Patients with non-inflammatory RMDs have also been affected by the pandemic, and appear to have similar levels of concern regarding COVID19 as those with inflammatory and autoimmune RMDs [4] . While telehealth has been an important tool in reducing healthcare disruptions during the pandemic, as shown in our study, it also is likely to serve an important purpose in healthcare delivery in the future.

It remains unclear how to best deliver telehealth care in outpatient rheumatology practices moving forward. Several important features may facilitate best practices. Telehealth care pathways can be used to identify the most appropriate patients to receive telehealth instead of in-office care -identifying which diagnoses and visit reasons are most suitable Accepted Article for telehealth care, which patients are most comfortable and satisfied with telehealth, and screening for access to technology needed to deliver telehealth [26] . New provider and patient education may be needed, teaching how to conduct a rheumatology exam over a live video feed and how to best instruct and assist patients in conducting their own standardized self-examination (e.g. a patient joint count for those with RA) [27] . Collecting disease-specific and diseaseagnostic electronic patient reported outcomes using a digital platform via a smartphone app and/or passive monitoring (e.g. health tracker device such as a Fitbit or Apple watch) may also be useful complements to delivering high quality remote patient care [12, 28] .

The results of this study highlight the importance of ensuring that telehealth does not exacerbate existing disparities in healthcare access. Recognizing that social determinants of health are associated with visit cancellations, practices should have processes to identify and contact patients with missed or cancelled visits. Interventions to improve access to and/or assistance in using telehealth technology is particularly important for vulnerable populations. Additionally, incorporating patient preferences for telehealth versus office visits and providing alternatives for patients uncomfortable with standard telehealth visits will be important. Identifying barriers to effective telehealth use and strategies to overcome these barriers is a significant area of need.

Results from this analysis must be contextualized considering its setting. This study reflects the experience of rheumatology providers in this high-volume, community practice-based network of approximately 300 community rheumatology providers distributed among 92 offices. While diverse, these clinicians' practice characteristics and patterns may not generalize to other community settings, nor academic medical centers, although our findings appear similar to early reports from smaller rheumatology provider networks [29] . Measures of social determinants of health were inferred based on patients' residence using their 9-digit zip code, which maps to census block group. This approach is commonly used in health services research, as this information is often not available directly from patients. The potential biases inherent to collecting socioeconomic status data from individual patients including the expected nonresponse bias likely offsets this limitation. Finally, as a nuance of the single-vendor EHR system used by these clinicians, the scheduling system allows a visit to be rescheduled by changing the date, but this will not be recognized as a cancelled visit. Thus, the actual cancellation rates may be higher than as shown in Figure 2 , although efforts are underway to remedy this limitation in the future. Finally, we note that telehealth services may be associated with greater (or worse) satisfaction according to patients and providers [11] , and may or may not achieve comparable outcomes as in-person visits [30] . These topics were out of scope for this analysis but will be fruitful as future directions.

In conclusion, we observed large disruptions in care during the COVID-19 pandemic partially offset by telehealth use, with evidence that telehealth continues to be an important part of care delivery. Telehealth and other technology-Accepted Article focused tools facilitating remote patient care and monitoring may be valuable to optimize outcomes, but these approaches need to be made more accessible, irrespective of the important social determinants of health that impact access to technology-enabled care. The substantial disparities we found in access to care for rheumatology patients during the pandemic based on age, socioeconomic status, and rural residence should be a call to action for rheumatology providers. Vulnerable populations should be prioritized, with specific strategies developed to reduce disparities in access to rheumatology care and maximize health and quality of life for these patients. 

This article is protected by copyright. All rights reserved 

Factors Associated With Use of Telemedicine for Follow-up of Rheumatoid Arthritis

A Systematic Review Exploring Pre-COVID-19 Telehealthcare Models Used in the Management of Patients with Rheumatological Disease

Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic

Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19

Effects of the COVID-19 Pandemic on Patients Living With Vasculitis

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment

Prevalence of hospital PCRconfirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

All rights reserved 10

Utilization of Telehealth Among Patients with Rheumatic Diseases in the Early Months of the COVID-19 Pandemic

Patient-Clinician Co-Participation in Design of an App for RA Management Via Telehealth Yields an App with High Usability and Acceptance

Satisfaction with rural rheumatology telemedicine service

Ability and Willingness to Utilize Telemedicine Among Rheumatology Patients -a Cross Sectional Survey

The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks

Prevention CfDCa: CDC Reports first known employee with COVID-19 Infection

Making Neighborhood-Disadvantage Metrics Accessible -The Neighborhood Atlas

US Coronavirus Cases and Deaths: Track COVID-19 data daily by state and county

Standard Distance in Univariate and Multivariate Analysis. The American Statistician

Virtually Perfect? Telemedicine for Covid-19

Using Telehealth to Expand Access to Essential Health Services during the COVID-19 Pandemic

Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic

Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician

Telerheumatology: A technology appropriate for virtually all

Can a Clinical Disease Activity Index Based on Patient-Reported Joint Counts (PT-CDAI) Be Used to Inform Target-Based Care in Telemedicine? An Analysis of 2 Early RA Cohort Studies

Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study

Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak

User Satisfaction With Telehealth: Study of Patients, Providers, and Coordinators. Health Care Manag (Frederick)

‡ County level data linked to the patient through 5-digit zip code; as of May 1 st

JIA=juvenile idiopathic arthritis; PsA=psoriatic arthritis